Wire · opportunities
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 November 2026 · Fusion42 review
The phase 3 LITESPARK-011 trial comparing belzutifan plus lenvatinib versus cabozantinib in advanced renal cell carcinoma showed improved progression-free survival and response rate for the combination, but overall survival difference was not statistically significant, possibly due to more subsequent therapies in the cabozantinib arm.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 9 Nov 2026 and 14 Nov 2026.
◆ ◆ The Wire takeaway
Your drug’s survival benefit may hide behind follow-up treatments shifting patient outcomes. Expect delayed separation of overall survival curves to reveal your combo's true impact.
◆ Coverage
2 sources · first reported 9 Nov 2026 · latest 14 Nov 2026
◆ Related on Wire
◆ Topics